Technology | EP Mapping and Imaging Systems | August 14, 2018

BioSig Technologies Announces FDA 510(k) Clearance for Pure EP System

Electrophysiology mapping system minimizes noise and artifacts in ECG and intracardiac signals during EP procedures

BioSig Technologies Announces FDA 510(k) Clearance for Pure EP System

August 14, 2018 — BioSig Technologies Inc. announced that the company received 510(k) clearance for its first product, Pure EP System, from the U.S. Food and Drug Administration (FDA).  

The non-invasive Pure EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data.  

The Pure EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures.

To date, BioSig has performed twelve pre-clinical studies at:

  • Mayo Clinic in Rochester, Minn.;
  • Three at UCLA Medical Center in Los Angeles; and
  • One at Mount Sinai Hospital in New York.

BioSig signed a 10-year collaboration agreement with Mayo Clinic in 2017 that will enable the company to advance the platform and expand its capabilities into other areas of clinical importance. The Journal of Innovations in Cardiac Rhythm Management published several years of pre-clinical data (https://www.biosigtech.com/technology/publications) conducted at Mayo Clinic.

Minnetronix, BioSig’s manufacturing partner in St. Paul, Minn., has produced initial systems that will allow the company to enter the market in the U.S. with selected sites.

One of the most common reasons for an EP procedure is the diagnosis and treatment of atrial fibrillation. Atrial fibrillation is the most common arrhythmia, currently affecting 33.5 million people worldwide, with 6.1 million people in the U.S. Atrial fibrillation increases the risk of stroke by 4 to 5 times and contributes to approximately 750,000 hospitalizations per year. According to the 2016 HRI Global Opportunities in Medical Devices & Diagnostics report, the current market of EP is estimated at $4.6 billion and growing at a 10.5 percent rate annually.

On Aug. 1, BioSig Technologies announced its intention to uplist to the Nasdaq exchange. The company expects to be trading on Nasdaq in 2018.

For more information: www.biosigtech.com

Related Content

An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Videos | EP Lab | January 03, 2019
This is a quick video tour of one of the dedicated...
HHS and NASA Team Up to Explore Health on Earth and in Outer Space

Image courtesy of NASA

News | EP Lab | December 14, 2018
The Department of Health and Human Services (HHS) recently entered into an interagency agreement with the National...
Technology Improvements Driving Electrophysiology Market Growth

Navik 3D Cardiac Mapping System image courtesy of APN Health.

News | EP Lab | December 10, 2018
December 10, 2018 — Electrophysiology, whil
Vagal Maneuvers With Supraventricular Tachycardia

Image courtesy of ACLS Certification Institute

Feature | EP Lab | December 05, 2018
Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic...
Societies Publish New Guidance for Treatment of Slow, Irregular Heartbeats
News | EP Lab | November 09, 2018
The American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Rhythm Society (HRS)...
A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Overlay Init